Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

Current Drug Safety

Volumn 4, Issue 3, 2009, Pages 229-237

  Citrome, Leslie ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absolute risk increase; Number needed to harm; Relative risk increase; Relative risk ratio

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADVERSE OUTCOME; AKATHISIA; AKINESIA; AUTISM; BIPOLAR DEPRESSION; BIPOLAR MANIA; BRADYKINESIA; CLINICAL TRIAL; DEMENTIA; DRUG CHOICE; DRUG EFFICACY; DRUG INFORMATION; DRUG LABELING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GERIATRIC PATIENT; HUMAN; HYPERKINESIA; HYPOKINESIA; LARYNX SPASM; MAJOR DEPRESSION; MORTALITY; MUSCLE HYPERTONIA; MUSCLE SPASM; MUSCLE TWITCH; OCULOGYRIC CRISIS; OFF LABEL DRUG USE; PARALYSIS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TETANY; TONGUE PARALYSIS; TORTICOLLIS; TREMOR; WEIGHT GAIN; ADULT; DRUG EFFECT; FEMALE; MALE; PATIENT; SAFETY;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; DRUG LABELING; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; PATIENT DROPOUTS; RISK ASSESSMENT; WEIGHT GAIN;

EID: 67749114366     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488609789006985     Document Type: Review

References (21)

1. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-2.
2. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008; 117: 412-9.
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Invega. Revised September 2008. Available at: http://www.janssen.com/janssen/ shared/pi/invega.pdf [Accessed: January 5, 2009].
4. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-12.
5. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM, Third ed. Edinburgh: Elsevier Churchill Livingstone 2005.
6. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-101.
7. Braithwaite W, Cole P, Feinstein AR, et al. The Role of Epidemiology in Decision-Making. The Annapolis Center, 1999. Available at: http://www.annapoliscenter.org [Accessed January 6, 2009].
8. Citrome L, Volavka J. Atypical antipsychotics: revolutionary or incremental advance. Expert Rev Neurotherapeut 2002; 2: 69-88.
9. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 2008; 7: 761-9.
10. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Risperdal. Revised August 2008. Available at: http://www.janssen.com/janssen/shared/ pi/risperdal.pdf [Accessed January 5, 2009].
11. Eli Lilly and Company. Zyprexa. Revised August 14, 2008. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf [Accessed January 5, 2009].
12. AstraZeneca Pharmaceuticals LP. Seroquel. Revised September 2008. Available at: http://www1.astrazeneca-us.com/pi/seroquel. pdf [Accessed January 5, 2009].
13. Roerig, Division of Pfizer Inc. Geodon. Revised June 2008. Available at: http://www.pfizer.com/files/products/uspi-geodon. pdf [Accessed January 5, 2009].
14. Bristol-Myers-Squibb, Otsuka America Pharmaceutical Inc. Abilify. Available at: http://packageinserts.bms.com/pi/pi-abilify. pdf [Accessed January 5, 2009].
15. Bonham C, Abbott C. Are second-generation antipsychotics a distinct class? J Psychiatr Pract 2008; 14: 225-31.
16. Ratey JJ, Salzman C. Recognizing and managing akathisia. Hosp Commun Psychiatry 1984; 35: 975-7.
17. Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008; 120(Jul): 18-33.
18. Ballard C, Waite J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD003476.
19. United States Food and Drug Administration. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. April 11, 2005. Available at: http://www.fda.gov/Cder/drug/advisory/ antipsychotics.htm [Accessed June 3, 2007].
20. Citrome L. Atypical antipsychotics, elderly patients, and mortality risk. South Med J 2007; 100: 964-5.
21. Cookson J, Keck PE, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007; 22: 93-100.